The closer the better: does better access to outpatient care prevent hospitalization? by Elek, Péter et al.
Vol.:(0123456789) 
The European Journal of Health Economics 
https://doi.org/10.1007/s10198-019-01043-4
ORIGINAL PAPER
The closer the better: does better access to outpatient care prevent 
hospitalization?
Péter Elek1,2  · Tamás Molnár3 · Balázs Váradi1,3
Received: 18 July 2018 / Accepted: 26 February 2019 
© The Author(s) 2019
Abstract
In 2010–2012, new outpatient service locations were established in poor Hungarian micro-regions. We exploit this quasi-
experiment to estimate the extent of substitution between outpatient and inpatient care. Fixed-effects Poisson models on 
individual-level panel data for years 2008–2015 show that the number of outpatient visits increased by 19% and the number 
of inpatient stays decreased by 1.6% as a result, driven by a marked reduction of potentially avoidable hospitalization (PAH) 
(5%). In our dynamic specification, PAH effects occur in the year after the treatment, whereas non-PAH only decreases with a 
multi-year lag. The instrumental variable estimates suggest that a one euro increase in outpatient care expenditures produces 
a 0.6 euro decrease in inpatient care expenditures. Our results (1) strengthen the claim that bringing outpatient care closer 
to a previously underserved population yields considerable health benefits, and (2) suggest that there is a strong substitution 
element between outpatient and inpatient care.
Keywords Administrative panel data · Inpatient care · Outpatient care · Potentially avoidable hospitalization ·  
Quasi-experiment · Substitution
JEL Classification C23 · C26 · I10
Introduction
How to best allocate limited public resources across outpa-
tient and inpatient healthcare services to achieve maximum 
improvement in health outcomes is one of the perennial 
questions of health policy all over the world.
To inch closer to answering that question, we have to 
understand, disentangle, and accurately measure the relation-
ships between those two levels of care. Does the provision 
of more outpatient care, while itself improving health out-
comes, also generate more hospitalization episodes and/or 
make them longer, or, to the contrary, does it help to avoid 
costlier inpatient care later on? What are the respective 
and aggregate changes in health care expenditures? In this 
paper, we use panel data from a quasi-experimental setting 
provided by an expansion of specialist outpatient care in 
Hungary between 2010 and 2012, greatly improving access, 
to contribute to answering those questions. Besides observa-
tional or cross-sectional studies, the earlier quasi-experimen-
tal literature mainly uses data from the United States, and 
hence, little is known about the substitution/complementa-
tion effects in countries whose health care sector is charac-
terised by different institutional and regulatory frameworks 
and financing arrangements.
At the highest level of abstraction, nationwide health 
policy planning is about maximizing health outcomes of 
the population constrained by limited public and private 
resources. This is done through financing many functional 
channels of the health care system, but, in OECD coun-
tries, most expenditure goes to curative and rehabilitative 
care, and, within that, two of the most important functions 
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are outpatient care, upon which 1.2–7.5% of gross domes-
tic product (GDP) is expended; and inpatient care, with 
1.5–3.4% of GDP (2015 data from [17]). Given these enor-
mous expenses, the importance of any reliable evidence that 
can contribute to even a marginal improvement of health 
outcomes by a better allocation of resources across these 
two subsectors cannot be overstated. Such evidence can help 
policy makers to decide whether additional public resources 
are put to better use by being channelled toward expanding 
outpatient or inpatient care. In what follows, we first present 
the possible mechanisms of substitution and complementa-
tion and the empirical literature so far, then the Hungarian 
context, followed by the data, the methods, our results and, 
finally, our conclusions.
Mechanisms of substitution 
and complementation
What are the possible theoretical mechanisms of interaction 
between inpatient and outpatient care? Fortney et al. [8], 
building on the work of Starfield [21] and others, identify the 
following mechanisms of substitution (i.e. more outpatient 
care decreases hospitalization) and complementation (more 
outpatient care reduces more inpatient care).
Mechanisms of substitution:
• Early detection of an illness in outpatient care can make 
treatment possible at that level and obviate the need for 
hospitalization. This substitution mechanism, they claim, 
could have both short-term (e.g. prevention of hospitali-
zation for asthma by prevention and early treatment of 
exacerbations) and long-term effects (e.g. prevention of 
stroke by the treatment of hypertension).
• The management of chronic health conditions in outpa-
tient care (e.g. routine testing or patient education) can 
also prevent or at least delay the need for inpatient care—
control of blood sugar to avert kidney failure in patients 
with diabetes mellitus is a classic example of this.
• Depending on the rules and incentives built into  the 
health care system of the country in question, doctors 
in outpatient care could have a formal gate-keeping role, 
as well: in many cases, their referral can be required for 
hospitalization.
Mechanisms of complementation:
• Treatment in outpatient care might call for supplemental 
or ancillary care provided in hospitals (e.g. diagnostic 
laboratory tests).
• The detection in outpatient care of illnesses (e.g. cancer, 
serious mental illness) that are best treated by a specialist, 
in hospital. This mechanism could especially affect patients 
who have not used primary care services for a long period 
of time and who have a greater number of undetected ill-
nesses.
• The identification (through close monitoring) of acute epi-
sodes of chronic illnesses that require specialty or inpatient 
treatment. This mechanism is particularly relevant for dis-
orders with symptoms that may fluctuate in severity over 
time (e.g. angina or major depressive disorder).
The empirical literature is rather mixed in terms of whether 
the substitution or the complementation effect dominates. 
Miller [15] analysing a Massachusetts reform (a health insur-
ance reform was introduced that differentially affected the 
costs of outpatient and inpatient care) and Rubinstein et al. 
[20] analysing the effects of a reorganization to increase 
access to primary care for veterans in Virginia both found a 
drop in hospitalization in response to more access to primary 
care. Other papers also found substitution effects in cross-
sectional settings [1, 6, 10, 19].
On the other hand, Kaestner and Sasso [11] found that, 
in the US, an increased outpatient spending was associated 
with more hospital admissions; the Rand and the Oregon 
health insurance experiments also showed that improving 
the availability of medical services through a more generous 
health insurance coverage was associated with an increase 
in the use of emergency room services and hospitalization 
[7, 16].
A third group of studies found neither substitution nor 
complementation effects. Looking into the same Massa-
chusetts reform as Miller [15], Kolstad and Kowalski [12] 
found that gaining insurance was associated with a decrease 
in hospital admissions through emergency department, an 
increase in hospital admissions through other channels, and 
no change in total hospitalizations. The instrumental vari-
ables analysis by Fortney et al. [8] indicated that an increase 
in primary care encounters was associated with a decrease 
in specialty medical encounters, but was not associated with 
an increase in physical health admissions or outpatient costs.
One promising method to try to sharpen the results in the 
empirical literature, exemplified by Duscheiko et al. [3], has 
been to narrow down the focus upon hospitalizations for con-
ditions considered especially sensitive to timely and effec-
tive management in primary care; e.g. Kolstad and Kowalski 
[12], whose inconclusive results put them in the “no effect” 
camp above, actually find a substitution effect when zooming 
in on the effects upon preventable hospitalization.
Institutional context
In addition to being, in sum, rather inconclusive, many of 
these studies are also observational or cross-sectional, mak-
ing the establishment of causal relationships hard. In the 
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case of papers based on a quasi-experimental or experimen-
tal setup, the source of variation that makes identification 
possible consists in changes in the financing (insurance) 
mechanism alone and almost all of them examine the US. 
Our source of variation is different and our evidence comes 
from a very different, but, by no means, internationally 
unique institutional setting, shared by most post-communist 
EU member states (e.g. Poland and the Czech Republic) and 
the countries emerging from the Soviet Union like Russia 
and Ukraine [14]. In such countries, our research question 
has never been addressed before.
Hungary is a post-communist EU member state of slightly 
less than 10 million inhabitants with a single-payer health 
insurance and de facto universal coverage [5]. In 2015, 
Hungary spent 7.2% of its GDP on health care, 1.8% of the 
GDP on outpatient (including government- and household-
financed primary and specialist outpatient) and 1.9% of the 
GDP on inpatient care [17]. The basic benefit package is free 
of out-of-pocket payments for the patients at the point of 
care (including outpatient care), although informal gratuity 
payments are widespread. Primary care by general practi-
tioners is financed by capitation; most outpatient services are 
financed by the budget based on fee-for-service points, under 
a system that scores procedures on the basis of their com-
plexity and resource requirements, whereas inpatient ser-
vices, almost exclusively provided in state-run and -financed 
hospitals, are reimbursed through a combined payment sys-
tem based on diagnosis-related groups (acute care) and per 
diem rates (chronic care).
The relatively high share of outpatient care in provision 
and financing is due to the heritage of the Semashko-type 
healthcare system, common in countries once under Soviet 
dominance. Central to that model was a multi-tiered system 
of care with a strict referral system and strongly differenti-
ated network of service providers, with outpatient specialist 
care, provided in dedicated polyclinics and thus separated 
from primary care, one of the distinct tiers of healthcare 
provision [9, 13]. Concentrating on the relationship between 
this type of care and inpatient care can, arguably, provide 
more precise information on substitution/complementa-
tion than what can be obtained in healthcare systems where 
data on primary and specialised outpatient care are lumped 
together. Given the institutional arrangement in Hungary, 
and to avoid confusion, in what follows, we will refer to 
“specialist outpatient” care, or, for brevity, “outpatient care” 
as disjoint from “primary care”, whereas we retain the term 
“ambulatory care” when referring to the general interna-
tional literature that uses this term subsuming primary care, 
as well. We will also address another subset of outpatient 
care, “1-day ambulatory care” later on.
The health status of the Hungarian population is among 
the poorest in the EU with a life expectancy at birth of 75.7 
years, tailing the EU average by 4.9 years, with even worse 
parameters in rural micro-regions in which the intervention 
which we use for identification took place.
The intervention which we base our quasi-experimen-
tal specification on is the same as used in Elek et al. [5]. 
Between 2010 and 2012, around 430,000 people gained 
better access to specialist outpatient care in Hungary when 
the government created outpatient units in 20 rural micro-
regions, which previously lacked capacity. The investments 
were funded by the Social Infrastructure Operative Pro-
gramme (SIOP) 2.1.2. of the European Union. Locations 
for the new units were selected based on the applications 
of municipalities, making a case for need and demand.1 
Funding accounted for 500–1000 million HUF (2–4 million 
euros) per unit, generally covering 90–95% of the costs of 
the establishment of the new units to the municipalities if 
they complied with a set of administrative requirements (e.g. 
providing a minimum of services for a minimum of hours/
month, keeping the unit in operation for at least 5 years). 
Competition for scarce funds was not an issue: sufficient 
funds were allocated to be able to subsidize all likely appli-
cants eligible under those rules. The newly created units (all 
still in operation as of 2016) provide comprehensive service 
for the population of the micro-regions with at least 14 sepa-
rate specialties at each location. As a result, basic special-
ist outpatient care in the following four specialties: internal 
medicine, surgery, obstetrics—gynaecology, and pediatrics 
may now be reached by around 310,000 more people by car 
in 20 min than before.
At the same time, the other parts of Hungary experienced 
relatively few changes in the management of outpatient 
care between 2008 and 2015. Hence, an appropriate con-
trol group of micro-regions could be identified, in which 
the health care indicators may be compared to those in the 
micro-regions where new outpatient service locations were 
established (the “treated” micro-regions). The impact of the 
improvement in accessibility can then be estimated as the 
difference between the changes in the treated and control 
groups, with a difference-in-difference-type analysis.
It is the treatment that we use in the paper to identify the 
sign, the magnitude, and the lag of the effect of more outpa-
tient treatment upon hospitalization at the individual level.
1 The decision to apply for EU-financed expansions had to do with 
the obligation of the local government to maintain the new outpatient 
units, financed with fee-for-service point reimbursement, which is a 
function of the expected number of patients. The latter could be esti-
mated from geography, population density, and the location of other 
healthcare providers.
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Data and descriptive statistics
We use anonymized individual-level administrative data on 
inpatient stays and specialist outpatient visits, exclusively 
provided to us for this research project by the Hungarian 
National Healthcare Services Centre (ÁEEK). Data cover 
years 2008–2015 for the population of 20 treated and 20 
control micro-regions with approximately 1,060,000 people 
in Hungary (around 10% of the population of the country). 
The control micro-regions were chosen with propensity 
score matching to approximate the pre-treatment demo-
graphic, socio-economic, and health characteristics of the 
treated micro-regions. Elek et al. [5] provide the details on 
the matching procedure as well as on the treated control 
balance in terms of the observed pre-treatment characteris-
tics.2 The balance is satisfactory in most variables, although 
there remains a slight—statistically not significant—differ-
ence in pre-treatment outpatient care provision. The num-
ber of weekly specialist outpatient consultation hours per 
1000 residents averaged to 0.6 in the treated and 1.2 in 
the control micro-regions in 2008, but the latter was still 
very small compared to the average value of all non-treated 
micro-regions in Hungary (3.8). We will control for this pre-
treatment difference by the fixed-effects models.
The annual panel data set used in our analysis contains 
for each person-year the number of inpatient stays (and of 
its certain subgroups, see below), the number of special-
ist outpatient visits (and of its certain subgroups), the esti-
mated inpatient and outpatient care expenditures, as well as 
demographic information such as gender, year of birth, and 
settlement of residence.3 Year of death is also recorded for 
those who died during the period. We omit newborns from 
the sample, and, hence, restrict the analysis to those at least 
2 years of age.
Annually, around 13% of the population of the control 
micro-regions was hospitalized. We also define potentially 
avoidable hospitalization (PAH), i.e. hospitalization due to 
ambulatory care sensitive conditions (ACSCs), based on the 
ICD-10 category of the primary diagnosis of the inpatient 
episode. Our main definition for PAH follows Purdy et al. 
[18] as described in detail by Eggli et al. [4].4 According 
to this definition, around 2.4% of the population was hos-
pitalized due to an ACSC in a given year. We classify this 
category into the following subgroups (see "Appendix 1" 
for details):
• cardiology-related conditions (angina, congestive heart 
failure, and hypertension) (0.8%),
• pulmonology-related conditions (asthma and COPD) 
(0.6%),
• diabetes complications (0.3%),
• conditions due to non-adequate specialist outpatient care 
(e.g. ear, nose, and throat infection) (0.3%), and
• conditions due to non-adequate primary care (e.g. influ-
enza) (0.6%).
Figure 1 shows that hospitalization case number, hospitali-
zation probability, as well as PAH probability decreased 
more in the population of the treated group than of the con-
trol group after 2010–2012, when the new outpatient units 
started to operate in the treated micro-regions.5 Most new 
units were established in 2011. The difference between the 
treated and control values was slightly positive or roughly 
zero before 2011, but became negative afterwards. We will 
also examine certain other subgroups of hospitalization such 
as acute and chronic episodes.
Meanwhile, according to Fig. 1, the number of outpatient 
visits jumped high in the treated compared to the control 
group after 2010–2012. The levels and trends are consistent 
with outpatient capacities: due to some existing outpatient 
units in the control micro-regions, outpatient care use was 
slightly higher in the control than in the treated group before 2 The previous study of Elek et al. [5], which focused on short-term 
patterns of outpatient care, used 21 control micro-regions. In the cur-
rent analysis, we exclude the micro-region of Szikszó, because acute 
inpatient care was abolished in its hospital during our examined 
period. The matched inpatient–outpatient data, used in the current 
study, had not yet been available at the time of writing of the past 
paper.
3 The data set covers only those people who appeared at least once in 
outpatient or inpatient care between 2008 and 2015. This is a negli-
gible restriction for two reasons. First, other administrative data (the 
linked labor-health panel data set processed by the Institute of Eco-
nomics, Centre for Economic and Regional Studies of the Hungarian 
Academy of Sciences, see, e.g. Bíró and Elek [2] for its health vari-
ables) suggest that less than 2.5% of the (18–74 years old) inhabitants 
of the examined micro-regions did not appear at all in either outpa-
tient or inpatient care during another 8 year long period (2003–2011). 
Second, we use fixed-effects Poisson and logit models in our main 
analysis, and the always zero observations drop out in the estimation 
of these models.
4 As a robustness check, we also defined PAH following the Euro-
pean Collaboration for Healthcare Optimization (ECHO) project 
[22], which examines hospitalization due to angina, congestive heart 
failure, and strictly defined diabetes complications for people at least 
40 years old, asthma and COPD for people at least 18 years old, and 
dehydration complications for people at least 65 years old. Our results 
do not change substantially when this alternative definition is used.
5 We note that the original data refer to only those inpatient events 
that started and also terminated within 2008–2015, and therefore, 
some inpatient stays are missing for 2015. All figures in the paper 
show the adjusted data for 2015 by assuming that inpatient events 
with year of discharge different from year of admission constituted 
the same share of all inpatient events in 2015 as in 2013–2014. This 
adjustment increases inpatient case numbers by only 1.2%, and does 
not affect substantially our later results. For details, see "Appendix 2".
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2011, but this difference quickly reversed when the new out-
patient units emerged in the treated micro-regions. We also 
note that, before 2011, outpatient case numbers in the treated 
group were well below the national average and also below 
(by 20–25%) those rural micro-regions that already had sub-
stantial outpatient capacities [5], so the sudden increase was 
just a catch-up from a low initial level in an underserved 
population.
We will specifically examine outpatient visits associated 
with certain ACSCs such as those in cardiology, pulmonol-
ogy, or diabetes, defined by the ICD-10 code of the outpa-
tient event. We hypothesize that a growing ratio of patients 
treated in outpatient care with such conditions may have 
caused the decreased prevalence of PAH.
Finally, the lower two graphs in Fig. 1 show that, while 
outpatient expenditures increased, the estimated inpatient 
expenditures decreased in the treated compared to the con-
trol micro-regions.6
Obviously, outpatient care use and inpatient care use are 
strongly correlated on the individual level. In the control 
micro-regions, patients hospitalized in a given year visited 
(non-laboratory) outpatient care 2.9 times more often in the 
previous year than non-hospitalized patients, and the dif-
ference persists when age and gender are controlled for. 
However, these cross-sectional correlations are non-causal. 
Estimation of a causal relationship between outpatient 
and inpatient care requires a quasi-experiment such as the 
establishment of the new outpatient locations in our case. 
Therefore we apply a difference-in-difference-type analysis 
Fig. 1  Per capita use of 
inpatient and (non-laboratory) 
outpatient care in the treated 
and control micro-regions
6 Individual-level expenditures are approximated based on the financ-
ing rules of the Hungarian health care system, but they cannot be 
calculated precisely from the data at hand, because some financial 
variables of minor importance are missing. Hence, our results on 
expenditures only give rough estimates on the financial interactions 
between outpatient and inpatient care.
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to measure the treatment effect (and check the pre-treatment 
parallel trends in the treated and control group with a pla-
cebo test). In support of our identification approach, it is 
important to also add that, although hospital capacities had 
been curtailed to save costs in 2007, before the time period 
under scrutiny, there was virtually no policy-driven change 
in the supply of inpatient care during the time-span which 
we analyse. Still, we use three explanatory variables to con-
trol for possible exogenous changes in health care supply in 
the examined period: the number of wider regional (county-) 
level number of hospital beds; the ratio of unfilled GP prac-
tices in the settlement of the individual; and the availability 
of special 1-day ambulatory services (aimed at providing 
certain treatments in internal care, neurology, and physi-
otherapy) that started to operate in some treated and control 
micro-regions in the examined period (see "Appendix 3" for 
details, and Table 10 in "Appendix 4" for descriptive sta-
tistics of these variables in the treated and control groups).
Beyond an impact assessment of the establishment of the 
new outpatient units, we use this quasi-experiment to esti-
mate the structural effect of bringing outpatient care 1 min 
closer to the residence of the individual on hospitalization. 
Therefore, we define the travel time (in minutes) needed to 
reach the nearest outpatient unit by car from the settlement 
of each individual. This distance measure decreased in the 
treated micro-regions from 24 min in 2008 to 10 min in 
2012, while it was essentially unchanged (21 min on aver-
age) in the control micro-regions.
Methods
Effects of the new outpatient locations
For person i in year t,  let yit denote the number of hospital 
admissions (or the number of its various subcategories), dit 
the dummy variable that equals one for the population of 
the treated micro-regions after the establishment of the new 
units and zero otherwise (i.e. zero always for the control 
group and before the establishments for the treated group), 
Tit the calendar year dummies, and zit the control variables (a 
cubic function of individual age and the health care supply 
variables described above). In our baseline models, we esti-
mate the effect of the treatment on the expected number of 
admissions, E(yit), with fixed-effects (FE) Poisson, and, for 
robustness check, with FE linear models. We also estimate 
the probability of hospitalization, Pr(yit > 0), with FE logit:
(1)E(yit) = exp(훽
poi
d
dit + 훽
poi
T
Tit + 훽
poi
z
zit + c
poi
i
)
(2)E(yit) = 훽 lind dit + 훽 linT Tit + 훽 linz zit + clini
where 훽 -s and 훾 -s are the parameters, ci -s denote the individ-
ual-level heterogeneity, and logit is the logistic function. We 
treat ci-s, the fixed effects, as completely unrestricted. They 
control for, among others, any pre-treatment differences in 
the health status of the individuals, and also for any time-
constant differences in individuals such as their gender. For 
the estimation of FE Poisson, FE linear, and FE logit models 
see Wooldridge [23].
We estimate further models with different dependent 
variables:
• Models (1)–(3) on the number of outpatient cases (FE 
Poisson and FE linear) and on the probability of receiv-
ing outpatient care (FE logit), for person i in year t, and 
on the ACSC-related outpatient subcategories.
• FE linear models on inpatient and outpatient expenditures 
of person i in year t.
Moreover, we investigate the heterogeneity of the effect of 
new outpatient locations on inpatient stays with various 
treatment interaction models (in FE Poisson and FE logit 
specifications):
• first, the treatment dummy is interacted with gender and 
age groups to examine potential heterogeneity across 
these categories;
• second, the treatment dummy is interacted with the indi-
cators of local supply of inpatient care such as the travel 
time between the micro-region and the nearest (substan-
tial) hospital7 or the capacity utilization rate of the beds 
in the nearest hospital;
• third, the (changing) travel time to the nearest outpatient 
service location is used as an additional explanatory vari-
able beyond the treatment dummy to examine the effects 
of the heterogenous improvement in outpatient availabil-
ity across settlements.
FE models estimate the treatment effect using within-person 
variation, i.e. by calculating how a person’s probability and 
frequency of health care use changed as a result of the treat-
ment compared to the control group. These models usually 
give more credible inference than e.g. pooled methods on 
panel data, because it is difficult to control for all individual-
level pre-treatment differences in the latter models. How-
ever, if there is a slight change in the probability of death in 
the treated compared to the control group (large effects are 
unlikely to occur in the 3–4 years after the establishments, 
(3)Pr(yit > 0) = logit(𝛾ddit + 𝛾TTit + 𝛾zzit + c
logit
i
),
7 The nearest substantial hospital is defined as the most frequent 
place of inpatient stay of the population of a micro-region.
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which we test with a pooled logit model), FE and pooled 
models may yield different estimates, because dying patients 
are selected out of the sample at a slightly different rate 
in the two groups. Therefore, we perform two robustness 
checks. First, we estimate pooled Poisson and logit models 
on inpatient and outpatient care use. For instance, the pooled 
Poisson specification is defined as follows:
where wit now contains additional controls such as gender 
(interacted with age) and the micro-region of the individual. 
Second, we estimate the FE Poisson and logit models (1)–(3) 
on the subsample of those who did not die during the 8 years 
long period.
Besides, we estimate dynamic treatment effects with ver-
sions of the above models. Let l(k)
it
= di,t−k − di,t−k−1 indicate 
the period exactly k years after the establishment of the new 
outpatient location in the micro-region of person i. Then, in 
the FE Poisson equation:
훽k (k = 0, 1, 2) measure the treatment effect exactly after k 
years, and 훽3+ shows the effect after 3 or more years. More 
lags cannot be included, because only about 4 years have 
passed after the initiation of the new outpatient locations. 
We use hospitalization, PAH, non-PAH case numbers, and 
probabilities as well as outpatient case numbers as depend-
ent variables in the dynamic models.
The parallel line assumption is crucial behind these 
models, i.e. that, after netting out the effect of the control 
variables, the outcome variables in the treated micro-regions 
would have changed in the absence of the treatment in the 
same way as they actually did in the control micro-regions. 
Therefore, we estimate a version of (5) for years 2008–2010, 
before the treatment:
where gi denotes the group of the (later) treated micro-
regions, I{t=k} the calendar year dummies, and we test 
whether 훽g,2008 = 훽g,2009 = 0, i.e. the group differences—
after controlling for the explanatory variables—are the same 
in 2008, 2009, and 2010, where the latter difference is cap-
tured by the individual fixed effects.
Substitution between outpatient and inpatient care
The most important advantage of the establishment of the new 
outpatient units is that we can exploit this quasi-experiment to 
(4)E(yit) = exp(훽
poi
d
dit + 훽
poi
T
Tit + 훽
poi
z
zit + 훽
poi
w
wit),
(5)
E(yit) = exp(훽0l
(0)
it
+ 훽1l
(1)
it
+ 훽2l
(2)
it
+ 훽3+di,t−3 + 훽TTit + 훽zzit + ci),
(6)
E(yit) = exp(훽g,2008 ⋅ gi ⋅ I{t=2008} + 훽g,2009 ⋅ gi ⋅ I{t=2009}
+ 훽TTit + 훽zzit + ci),
estimate the causal impact of more frequent outpatient care use 
on inpatient care use. Formally, we estimate fixed-effects linear 
instrumental variable (FE IV) models of the form:
where, in the baseline IV specification, yit is the number of 
hospital admissions and xit is the number of outpatient care 
visits for person i in year t,  and xit is instrumented with dit, 
the treatment dummy. The reduced form and the first stage 
of this model are the FE linear models (2) of inpatient and 
outpatient case numbers, respectively. Here, we use a linear 
model, because fixed-effects and instrumental variables are 
computationally not straightforward to incorporate simulta-
neously in a Poisson specification.
We also estimate the substitution/complementation effect 
in terms of outpatient and inpatient expenditures, i.e. using 
inpatient expenditures as the dependent variable and outpatient 
expenditures as the endogenous explanatory variable, instru-
mented by the treatment variable, in an FE IV model.
Furthermore, the long panel data set at our disposal enables 
us to measure the dynamics using contemporary and lagged 
outpatient care use variables as endogenous explanatory vari-
ables, instrumented by the contemporary and lagged treatment 
dummies. Formally, we estimate FE IV models of the form:
where xit and xi,t−1 are (jointly) instrumented by dit and di,t−1. 
Here, we only include one lag, since the pre-treatment period 
contains only 2 or 3 years for most micro-regions.
Results
Table 1 presents the estimated treatment effects on the use 
of inpatient and outpatient care. Descriptive statistics of the 
variables used in the models are shown in Tables 8, 9 and 10 
of "Appendix 4". The left panel displays the annual baseline 
probabilities of receiving a certain type of care in the control 
group, along with the effects of the treatment on these prob-
abilities. Odds ratios (i.e. exp(훾d) ) are shown, which roughly 
correspond in the case of inpatient care to multiplicative 
changes in probabilities, because hospitalization is relatively 
rare in the population. The right panel gives the baseline case 
numbers (per 100 inhabitants), the multiplicative effects of the 
treatment according to the FE Poisson models, i.e. exp(훽poi
d
), 
and the additive effects 훽 lin
d
 according to the FE linear mod-
els. The lower panel of the Table contains the baseline health 
expenditure values in the control group and how the treatment 
affects them.
Inpatient care
The upper panel of Table 1 shows that both the odds of 
hospitalization and the number of hospital admissions 
(7)E(yit) = 훿xxit + 훿TTit + 훿zzit + ci,
(8)E(yit) = 훿0xit + 훿1xi,t−1 + 훿TTit + 훿zzit + ci,
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decreased by about 1.5% as a result of the establishment of 
new outpatient units. In relative terms, the FE linear model 
gives an even stronger negative effect at the baseline value 
(− 0.63 per 21.3, i.e. − 2.9%). Non-ACSC related hos-
pitalization remained essentially unchanged (although 
the FE linear model shows a small absolute reduction), 
while ACSC-related inpatient stay decreased substantially 
(odds by 7%, case number by 5–8%). This was driven by 
a reduction in cardiology, diabetes-related, and specialist 
care specific PAH, which have ORs around 0.91–0.93, but 
the FE linear specification gives negative coefficients for 
all the categories.
According to the lower panel of Table 1, per capita inpa-
tient expenditures decreased by 820 HUF (2.8 euros) or by 
2.5% of the average expenditure, at about the rate of the 
reduction of inpatient case numbers. This suggests a roughly 
constant case mix (expenditure per inpatient episode).
Outpatient care
According to the middle panel of Table 1, the improved 
accessibility of ambulatory care increased outpatient case 
numbers by 19% in the non-laboratory and 15% in the 
Table 1  Effects of the establishment of new outpatient locations
Probability of not PAH refers to the probability that all inpatient stays are not PAH in a year
Baseline: the average values in the control group
Spec./prim. care spec.: PAH due to non-adequate specialist outpatient/primary care
Cluster-robust standard errors (SE) are displayed for all models apart from FE logit
Controls: fixed effects, cubic age, calendar year dummies, health care supply variables
Number of observations: 7,412,000. Number of periods: 8. Number of people: 1,037,000
PAH potentially avoidable hospitalization
***p < 0.01, **p < 0.05, * p < 0.1
Probabilities Case numbers
Baseline (%) FE logit Baseline (/100) FE Poisson FE linear
Odds ratio Multipl. effect Effect (per 100)
Est. SE Est. SE Est. SE
Inpatient care
   Overall 13.3 0.985** (0.006) 21.3 0.984** (0.006) − 0.63*** (0.12)
   Not PAH 11.9 0.998 (0.006) 18.4 0.991 (0.007) − 0.38*** (0.12)
   PAH 2.4 0.932*** (0.012) 2.9 0.950*** (0.013) − 0.25*** (0.033)
      Cardiology 0.80 0.906*** (0.019) 0.93 0.909*** (0.020) − 0.095*** (0.018)
      Pulmonology 0.58 1.005 (0.027) 0.74 1.035 (0.030) − 0.066*** (0.017)
      Diabetes 0.27 0.934** (0.032) 0.31 0.945 (0.033) − 0.017* (0.011)
      Spec. care spec. 0.31 0.932** (0.030) 0.32 0.935* (0.033) − 0.021** (0.010)
      Prim. care spec. 0.59 0.981 (0.024) 0.61 0.975 (0.027) − 0.047*** (0.014)
Outpatient care
   Overall non-lab. 54.6 1.232*** (0.005) 293.0 1.185*** (0.004) 53.0*** (0.94)
      Cardiology 5.8 1.290*** (0.011) 11.0 1.209*** (0.011) 2.8*** (0.11)
      Pulmonology 4.2 1.203*** (0.013) 8.7 1.043*** (0.012) 0.25** (0.097)
      Diabetes 2.3 1.325*** (0.025) 5.3 1.204*** (0.015) 1.2*** (0.073)
   Overall lab. 31.4 1.107*** (0.005) 105.0 1.148*** (0.006) 17.0*** (0.55)
      Cardiology 1.7 2.586*** (0.037) 2.9 1.786*** (0.035) 2.8*** (0.065)
      Pulmonology 0.33 1.349*** (0.050) 0.70 1.126** (0.060) − 0.16*** (0.030)
      Diabetes 0.76 3.118*** (0.079) 1.4 2.038*** (0.050) 1.2*** (0.036)
Expenditures
Baseline
(1000 HUF)
FE linear
Effect SE
Inpatient 32.6 − 0.82*** (0.26)
Outpatient 9.9 1.28*** (0.040)
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laboratory segment.8 Cardiology and diabetes-related out-
patient case numbers grew faster, while pulmonology-related 
case numbers increased slower than average. Remarkably, 
the number of laboratory tests with ACSC-related cardiol-
ogy and diabetes diagnoses roughly doubled, and the ratio 
of patients having annually at least one laboratory test with 
such diagnoses approximately tripled. Since the standard 
protocol for the treatment of diabetes mellitus includes regu-
lar blood tests such as HbA1c screening to check long-term 
blood glucose levels, this suggests that a growing number of 
diabetes patients became treated according to the protocol, 
implying a health gain for the population.
Finally, the lower panel of the table shows that per capita 
outpatient expenditures increased by about 1300 HUF (4.4 
euros), which is larger in absolute terms than the decrease of 
inpatient care expenditures.9 The additional costs make up 
about 13% of the average expenditure, in good accordance 
with the estimated effect on outpatient case numbers.
Heterogeneity and robustness checks
According to the heterogeneity analyses (not shown here in 
detail), the relative treatment effect—the logit odds ratio or 
the Poisson multiplicative effect—is not significantly differ-
ent across gender and age groups. Similarly, the local supply 
of inpatient care—the distance to the nearest hospital or the 
capacity utilization rate of beds there—does not significantly 
influence the effect of the new outpatient locations on inpa-
tient stays (p values of the treatment interaction terms exceed 
0.1 in all the specifications). At the same time, the differential 
reduction of the distance to the nearest outpatient location—
which varies across the treated micro-regions—has an addi-
tional explanatory power beyond the treatment dummy on 
the reduction of inpatient stays. In other words, the number 
of inpatient stays decreased statistically significantly more in 
settlements with greater improvement in travel time. These 
results—effect heterogeneity in the outpatient and homoge-
neity in the inpatient dimension—suggest the exclusive role 
of the outpatient channel in the reduction of inpatient stays, 
and, hence, give indirect evidence for the exogeneity of the 
treatment dummy as an instrument in the substitution analy-
sis between outpatient and inpatient care below.
Table 2 displays the effects of the reduction in travel time 
to the nearest outpatient care provider by car on hospitali-
zation.10 A 10-min reduction in travel time decreases PAH 
much more strongly than non-PAH ( OR = 0.965 vs. 0.989, 
i.e. the change in odds is threefold for PAH), and cardiology 
and diabetes-related PAH are particularly influenced.
Tables  4 and  5 in "Appendix  4" contain robustness 
checks. According to Table 4, the slightly negative effect on 
hospitalization, the more substantial negative effect on PAH 
and the large positive effect on outpatient care use persist in 
pooled models or in FE models restricted to those who did 
not die during the examined period. Table 4 also shows that 
death was not affected statistically significantly by the new 
outpatient locations in the medium term.
Table 5 of "Appendix 4" displays that, although the 
probability of chronic hospitalization (including rehabili-
tation and nursing services) decreased more than average 
( OR = 0.95 ), the probability of “core” hospitalization (i.e. 
acute admissions with at least one night in the hospital) also 
decreased ( OR = 0.989 ), with marked reduction among 
acute PAH ( OR = 0.95 ). According to the table, the results 
are not governed by the creation of the special 1-day ambu-
latory services in some treated and control micro-regions, 
because similar treatment effects are estimated when the 
sample is restricted to those micro-regions where the newly 
founded 1-day services had lower than median availability 
(as measured by per capita case numbers) after 2011.
Table 2  Effects of bringing outpatient care closer by 10 min with car
See Table 1 for details
***p < 0.01, **p < 0.05, * p < 0.1
Probabilities Case numbers
FE logit FE Poisson
Odds ratio Multipl. effect
Inpatient care Est. SE Est. SE
Overall 0.984*** (0.003) 0.991*** (0.003)
Not PAH 0.989*** (0.003) 0.993* (0.004)
PAH 0.965*** (0.007) 0.980*** (0.007)
 Cardiology 0.957*** (0.012) 0.958*** (0.013)
 Pulmonology 0.996 (0.014) 1.021 (0.014)
 Diabetes 0.959** (0.019) 0.949*** (0.020)
 Specialist care specific 0.974 (0.018) 0.971 (0.020)
 Primary care specific 0.961* (0.013) 0.983 (0.016)
10 These specifications do not contain the treatment dummy, only the 
travel time to the nearest location, because the former is not statisti-
cally significant when the latter is included in the regression.
8 This is in line with the short-term results by Elek et  al. [5], who 
could only examine the outpatient data up until 2012 (and inpatient 
data were not available then) and could not distinguish the various 
outpatient diagnoses.
9 Comparison of outpatient and inpatient spending is further com-
plicated by the fact that drugs prescribed in ambulatory care are par-
tially financed by out-of-pocket co-payment by the patient, whereas, 
in inpatient care, the full cost of medication is borne by the hospital 
and, thus, factored into the amount of the reimbursement. However, 
aggregate pharmaceutical consumption trends are roughly parallel in 
the treated and control group, so this effect is negligible.
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Dynamic effects
Figure  2 shows the estimated 훽k parameters from the 
dynamic equation (5). The numerical values of the param-
eters, along with robustness checks from FE and pooled logit 
models, are displayed in Table 7 of "Appendix 4". While 
outpatient case numbers responded quickly to the open-
ing of the new locations, inpatient case numbers reacted 
with a lag (and decreased by 2–3% after 3 years). Accord-
ing to the right panel of the figure, the lagged reaction was 
caused by non-PAH case numbers that became statistically 
significantly reduced by the end of the period, while PAH 
case numbers decreased right after the opening of the new 
locations.
The test of the pre-treatment parallel line assumption, 
detailed in Table 6 of "Appendix 4", shows that inpatient 
case numbers and its two subcategories changed in a roughly 
parallel way in the treated and the control micro-regions 
before the treatment. If anything, hospitalization in the 
treated micro-regions grew a bit—but statistically not sig-
nificantly—faster compared to the control micro-regions, so 
the rate of decrease after the treatment might even be slightly 
underestimated. Meanwhile, the parallel line assumption is 
rejected for outpatient case numbers, but the estimated dif-
ference in slopes (around 1%) is negligible compared to the 
change after the treatment (19%).
Substitution between outpatient and inpatient care
Table 3 shows the estimated structural effects of increased 
outpatient care use on inpatient care use (as measured by 
case numbers and expenditures), when the outpatient indica-
tors are instrumented with the treatment dummy. The static 
estimates suggest that one more (non-laboratory) outpa-
tient case of the patient decreases the number of hospital 
admissions by about 0.01 and a one HUF increase in outpa-
tient expenditures implies a 0.6 HUF reduction in inpatient 
expenditures. According to the dynamic models that contain 
the outpatient indicators and their lags (instrumented by the 
treatment dummy and its lag), the reduction in the use of 
inpatient care seems to occur with a lag. This is consistent 
with the hypothesis that improved outpatient care decreases 
the need for inpatient care through the better availability of 
prevention and treatment of chronic diseases.
The above structural results hold only if the instrument 
is appropriate (relevant and exogenous) in this setting. Rel-
evance is shown by the strength of the first stages, i.e. by 
the high t values of the treatment dummies in the FE lin-
ear models on outpatient care in Table 1 ( t = 56.4 for case 
numbers and 32.0 for expenditures). The exogeneity of the 
instrument cannot be proven formally, but, as discussed ear-
lier, the institutional framework (the application procedure 
of local governments), the lack of other major changes in 
the health care system during the examined period, and the 
treatment effect interactions all give indirect evidence for it.
Conclusions
Our quasi-experimental estimates indicate that bringing out-
patient care closer to a previously underserved population 
may yield considerable effects and not just short-term ones.
Fig. 2  Dynamic effects of the 
establishment of new outpatient 
locations on case numbers (with 
95% confidence intervals). For 
exact numbers, see Table 7 of 
"Appendix 4"
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As already shown in Elek et al. [5] on a shorter period, 
indicators of outpatient care use (expenditures and number 
of visits) increased right after the new outpatient centres 
were established.
But what is the effect of more access to specialist outpatient 
services upon inpatient care? Controlling for health care sup-
ply variables, fixed effects, and patient age, we find marked 
substitution effects between outpatient care and hospitaliza-
tion. As theory predicts, there is smaller effect upon inpatient 
care when leaving out potentially avoidable hospitalization due 
to ambulatory care sensitive conditions, but it is larger when 
concentrating upon potentially avoidable hospitalization. It 
is especially strong in the two specialisations of diabetes and 
cardiology. In the case of these two fields, we find correspond-
ing sizeable increases in outpatient laboratory case numbers, 
strengthening the case that, out of the different theoretical 
mechanisms, here, the substitution channel of management of 
chronic health conditions in outpatient care is of great impor-
tance. In these specialisations, substitution clearly dominates 
potential complementation mechanisms.
The dynamics of the effects is also noteworthy: as can be 
expected the substitution effects are stronger if we allow for a 
lag of several years for the additional outpatient care to take 
effect. The substitution effect upon potentially avoidable hos-
pitalization (PAH) is exerted more rapidly than upon hos-
pitalization for the other diagnostic groups, indicating that, 
in those specialisations, direct substitution mechanisms are 
present. We interpret the fact that, with a lag of several years, 
the substitution effect upon non-PAH also becomes signifi-
cant as a sign that, in addition to prevention due to the early 
detection, other, slower mechanisms of substitution, notably, 
better management of chronic conditions are also present. 
This suggests the presence of medium-term health benefits, 
although we cannot measure them directly using the available 
data. Thus, in terms of health policy implications, while we 
have no conclusive evidence of bringing outpatient care closer 
upon health outcomes, those effects are likely to be positive.
Finally, the effects concerning expenditures are also sig-
nificant and sizable. Even though the official Hungarian 
reimbursement fees may not exactly reflect variable social 
costs of the treatment (and fix costs are not addressed at all), 
we consider it remarkable that, according to our estimates, 
the extra (variable) cost of additional outpatient care (HUF 
1300) is partially cancelled out by savings in financing the 
hospitalization of the patients in question (HUF 800).
What is the external validity of our results vis-a-vis other 
countries? We can only speculate, but it stands to reason that 
the more similar the institutional and incentive framework of 
a healthcare provision to that of Hungary, the more likely that 
our findings carry over. Thus, we expect that post-communist 
countries with Semashko-type healthcare setup are the most 
likely to exhibit a similar substitution relationship between 
outpatient and inpatient care, but the relationship that we find 
could also be true for the other countries with single-payer 
healthcare systems. In as much as our findings for potentially 
avoidable hospitalization reflect the medical reality of man-
aging chronic health conditions in outpatient vs. inpatient 
care, they should hold in all the developed countries.
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Table 3  Structural effects 
of increased outpatient care 
indicators on inpatient care 
indicators
Cluster-robust standard errors are displayed
Instrumental variables: treatment dummy and its lag. Controls: fixed effects, cubic age, calendar year dum-
mies, and health care supply variables. Model: FE IV.
***p < 0.01, **p < 0.05, * p < 0.1
Parameter Lagged parameter
Est. SE Est. SE
Dependent var.: inpatient case number
Endogenous explanatory var:
 Outpatient case number − 0.010*** (0.0034)
 Outpatient case number and its lag − 0.0058 (0.0035) − 0.013*** (0.0033)
Dependent var.: inpatient expenditure
Endogenous explanatory var:
 Outpatient expenditure − 0.642*** (0.215)
 Outpatient expenditure and its lag − 0.292 (0.356) − 0.511* (0.284)
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Appendix 1: Potentially avoidable 
hospitalization (PAH)
Category ICD-10 code
Cardiology
   Angina I20, I240, I248, I249, I250, R072, 
R073, R074, Z034, Z035
   Congestive heart failure I11, I130, I255, I50, J81
   Hypertension I10, I1191
Pulmonology
   Asthma J450, J451, J458, J459, J46
   COPD J20, J40, J41, J42, J43, J44, J47
   Diabetes E10, E11, E12, E13, E14
Specialist care specific
   Ear, nose, throat infections H66.0, H66.1, H66.2, H66.3, 
H66.4, H66.9, H67, J02, J03, 
J040, J06, J312
   Convulsions, epilepsy G253, G40, G41, O150, O151, 
O152, O159, R560, R568
   Dental conditions A690, K02, K03, K04, K05, K06, 
K08, K098, K099, K12, K13
   Pelvic inflammatory disease N70, N73, N74
   Perforated/bleeding ulcer K20, K210, K219, K221, K226, 
K250, K251, K252, K254, 
K255, K256, K260, K261, 
K262, K264, K265, K266, 
K270, K271, K272, K274, 
K275, K276, K280, K281, 
K282, K284, K285, K286, 
K920, K921, K922
   Pyelonephritis N10, N11, N12, N136, N159, 
N300, N308, N309, N390
Primary care specific
   Cellulitis I891, L01, L02, L03, L04, L080, 
L088, L089, L88, L980
   Gangrene R02
   Dehydration, gastroenteritis A020, A04, A059, A072, A080, 
A081, A083, A084, A085, A09, 
K52
   Influenza, pneumonia A481, A70, J10, J11, J12, J13, 
J14, J153, J154, J157, J159, 
J160, J168, J181, J182, J188, 
J189
   Iron or other nutr. def. 
anaemia
D500, D508, D509, D510, D511, 
D512, D513, D518, D520, 
D521, D528, D529, D531, 
D571, D580, D581, D590, 
D591, D592, D599, D601, 
D608, D609, D610, D640, 
D641, D642, D643, D644, D648
Category ICD-10 code
   Nutritional deficiency E40, E41, E42, E43, E550, E643
   Other vaccine prev. diseases A35, A36, A37, A80, B05, B06, 
B161, B169, B180, B181, B26, 
G000, M014
Only primary diagnoses were considered, because secondary diagno-
ses were not available
Age was restricted to at least 2 years
Categorization is based on Purdy et al. [18]
Appendix 2: Missing inpatient stays in 2015
The original sample refers to only those inpatient events that 
started and also terminated within 2008–2015, and therefore, 
some inpatient stays are missing for 2015. All figures in the 
paper show adjusted data for 2015 by assuming that inpatient 
events with year of discharge different from year of admission 
constituted the same share of all inpatient events in 2015 as in 
2013–2014. This adjustment increases inpatient case numbers 
by only 1.2% but inpatient expenditures by 4.5% for 2015, 
because longer and, hence, more expensive inpatient stays are 
more likely to carry over to the next year than shorter ones.
The estimation results are essentially unaffected by this 
sample restriction. If a small share of inpatient events is 
missing randomly in 2015 in the treated and the control 
group, the selection effect is completely captured by the cal-
endar year dummy in the FE Poisson model because of its 
multiplicative structure, and the situation is similar in the FE 
logit model, because the modelled probabilities are small.
In principle, the FE linear model of the expenditures may 
be more sensitive to the sample restriction. However, if we 
impute the additional 4.5% of expenditures for 2015 using 
the patterns of the previous years, it only changes the elastic-
ity in Table 3 by about 0.01.
Appendix 3: Health care supply variables
We control for local health care supply with the following 
variables in our regressions.
First, possible changes in inpatient capacities in the 
micro-region or the wider region may have influenced 
hospitalization rates differently in the treated and control 
groups. Apart from the micro-region of Szikszó (which was 
excluded from the control group, exactly because acute inpa-
tient care was abolished there, implying a sudden reduction 
in the rate of hospitalization for its inhabitants), the other 
examined micro-regions did not have substantial inpatient 
capacities (hospital beds) throughout the whole observed 
period, so there is no need to control for inpatient supply on 
the micro-regional level. At the same time, we control for 
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the logarithm of the wider regional (county-) level number 
of hospital beds in our regressions.
Second, we control for the availability of GP care using 
the ratio of unfilled GP practices in the settlement of the 
individual.
Third, at the time of the establishment of the new outpa-
tient units, special 1-day ambulatory services started to oper-
ate in some treated and control micro-regions, which were 
aimed at providing certain treatments in internal care, neurol-
ogy, and physiotherapy at the ambulatory level instead of the 
hospital level. These new services may have had some subtle 
substitution effect between outpatient and inpatient care. We 
control for their local availability using the annual micro-
regional per capita level of the number of 1-day ambulatory 
cases in our regressions. Since such services were established 
only in around half of the treated micro-regions (and also 
in some control micro-regions), this local availability proxy 
can be included in our models. We also perform robustness 
checks (see Table 5 in "Appendix 4") to show that our results 
are not governed by these 1-day ambulatory services.
Appendix 4: More details of the estimated 
models
See Tables 4, 5, 6, 7, 8, 9 and 10.
Table 4  Estimates from pooled 
models and restricted FE 
models
Probability of not PAH refers to the probability that all inpatient stays are not PAH in a year
See Table 1 for baseline probabilities and case numbers. Baseline probability of death: 1.2%
Cluster-robust standard errors are displayed for all models apart from FE logit
Controls for pooled models: cubic age interacted with gender, calendar year dummies, micro-region of resi-
dence, and health care supply variables
Controls for FE models: fixed effects, cubic age, calendar year dummies, and health care supply variables
Restricted FE models are estimated on the sample of those who did not die in the examined period
Number of observations: 7,412,000. Number of periods: 8. Number of people: 1,037,000
PAH potentially avoidable hospitalization
***p < 0.01, **p < 0.05, * p < 0.1
Pooled models Restricted FE models
Probabilities Case numbers Probabilities Case numbers
Logit Poisson Logit Poisson
Odds ratio Multipl. effect Odds ratio Multipl. effect
Est. SE Est. SE Est. SE Est. SE
Death 1.012 (0.017)
Inpatient care
 Overall 0.994 (0.005) 0.986** (0.006) 0.985** (0.006) 0.981*** (0.006)
 Not PAH 1.003 (0.005) 0.994 (0.007) 0.998 (0.006) 0.989 (0.007)
 PAH 0.939*** (0.012) 0.936*** (0.011) 0.916*** (0.013) 0.936*** (0.014)
Outpatient care
 Overall non-lab. 1.169*** (0.004) 1.181*** (0.004) 1.231*** (0.005) 1.192*** (0.004)
 Overall lab. 1.078*** (0.004) 1.124*** (0.006) 1.109*** (0.005) 1.147*** (0.006)
Table 5  Robustness checks of the treatment effect on inpatient prob-
abilities
Controls: see Table 1. Model: FE logit
In the lower panel, the sample was restricted to those micro-regions 
that had lower than median per capita case number of special 1-day 
ambulatory services after 2011. It contains the population of 10 
treated and all but one control micro-regions
***p < 0.01, **p < 0.05, * p < 0.1
Odds ratio
Est. SE
Acute and chronic care
 Acute care (excluding 1-day care) 0.989* (0.0061)
 Acute PAH 0.954*** (0.013)
 Cardiology 0.949** (0.023)
 Pulmonology 0.992 (0.030)
 Diabetes 0.923** (0.035)
 Specialist care specific 1.010 (0.036)
 Primary care specific 0.969 (0.026)
 Chronic care 0.949*** (0.015)
Sample restricted to micro-regions with low availability of special 
1-day services
 Overall hospitalization 0.989 (0.0069)
 PAH 0.950*** (0.015)
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Table 6  Testing the parallel line assumption on case numbers for years 2008–2010
Cluster-robust standard errors are displayed
Controls: see Table 1. Model: FE Poisson
***p < 0.01, **p < 0.05, * p < 0.1
Multiplicative interaction terms of
treated vs. control group with years
p value of
both terms = 1
2008 vs. 2010 2009 vs. 2010
Est. SE Est. SE
Overall non-lab outpatient care 0.984*** (0.0044) 0.994 (0.0042) 0.001
Overall inpatient care 0.984* (0.0091) 0.995 (0.0085) 0.174
PAH 0.972 (0.020) 0.968* (0.018) 0.188
Not PAH 0.984 (0.0099) 0.999 (0.0093) 0.170
Table 7  Dynamic effects of the establishment of new outpatient locations
Controls: see Tables 1, 2, 3 and 4
***p < 0.01, **p < 0.05, * p < 0.1
0 year 1 year 2 years 3 + years
Est. SE Est. SE Est. SE Est. SE
FE Poisson for outpatient case numbers
 Overall non-lab 1.186*** (0.0098) 1.151*** (0.010) 1.169*** (0.010) 1.176*** (0.010)
FE Poisson for inpatient case numbers
 Overall 0.999 (0.0059) 0.989* (0.0060) 0.979*** (0.0059) 0.971*** (0.0053)
 PAH 0.952*** (0.018) 0.940*** (0.018) 0.963* (0.020) 0.953** (0.019)
 Not PAH 1.007 (0.0090) 0.999 (0.0097) 0.984 (0.0098) 0.976** (0.0093)
FE logit for inpatient probabilities
 Overall 1.005 (0.0090) 0.993 (0.0091) 0.975*** (0.0089) 0.973*** (0.0079)
 PAH 0.928*** (0.019) 0.926*** (0.019) 0.936*** (0.019) 0.929*** (0.017)
Pooled logit for inpatient probabilities
 Overall 1.016** (0.0075) 0.995 (0.0077) 0.980*** (0.0076) 0.984** (0.0069)
 PAH 0.943*** (0.016) 0.931*** (0.016) 0.940*** (0.017) 0.927*** (0.015)
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Table 8  Descriptive statistics of inpatient dependent variables
Control micro-regions Treated micro-regions
2008–2009 2010–2012 2013–2015 2008–2009 2010–2012 2013–2015
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Inpatient probabilities (%)
 Overall 13.55 34.22 13.22 33.87 13.13 33.77 13.64 34.32 13.38 34.05 13.04 33.68
 Not PAH 12.07 32.58 11.82 32.28 11.81 32.27 12.15 32.67 12.00 32.49 11.76 32.21
 PAH 2.52 15.66 2.40 15.31 2.29 14.96 2.48 15.56 2.37 15.20 2.19 14.65
 Cardiology 0.83 9.08 0.79 8.88 0.80 8.89 0.77 8.77 0.74 8.59 0.71 8.38
 Pulmonology 0.61 7.80 0.60 7.71 0.54 7.30 0.62 7.84 0.57 7.50 0.53 7.25
 Diabetes 0.35 5.90 0.27 5.21 0.22 4.65 0.37 6.03 0.30 5.43 0.23 4.74
 Specialist care spec. 0.32 5.64 0.31 5.55 0.31 5.58 0.29 5.35 0.29 5.41 0.29 5.42
 Primary care spec. 0.58 7.63 0.60 7.75 0.59 7.68 0.60 7.75 0.64 7.95 0.59 7.67
Inpatient case numbers (per 100 inhabitants)
 Overall 21.68 78.31 21.18 75.98 21.13 77.32 21.58 75.79 21.37 75.84 20.71 74.65
 Not PAH 18.61 72.62 18.23 70.17 18.35 72.02 18.60 70.33 18.52 70.41 18.08 69.65
 PAH 3.07 22.31 2.95 22.10 2.78 21.20 2.98 21.47 2.85 21.15 2.62 20.32
 Cardiology 0.96 11.67 0.92 11.49 0.92 11.55 0.89 11.09 0.86 11.00 0.81 10.79
 Pulmonology 0.79 12.17 0.77 12.05 0.69 11.22 0.76 11.22 0.70 10.8 0.64 10.36
 Diabetes 0.40 7.50 0.31 6.56 0.24 5.68 0.41 7.35 0.33 6.66 0.25 5.77
 Specialist care spec. 0.32 6.23 0.32 6.44 0.32 6.30 0.30 6.11 0.31 6.26 0.30 6.05
 Primary care spec. 0.60 8.39 0.63 8.79 0.61 8.53 0.63 8.91 0.66 9.05 0.62 9.03
Inpatient expenditures (1000 HUF/inhabitant)
 Overall 33.14 157.58 32.35 159.07 32.60 158.06 32.65 154.41 32.40 153.5 31.84 155.89
 N. of obs. 944,550 1,427,989 1,426,575 893,343 1,356,140 1,363,032
Table 9  Descriptive statistics of outpatient dependent variables
Control micro-regions Treated micro-regions
2008-20-09 2010–2012 2013–2015 2008–2009 2010–2012 2013–2015
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Outpatient probabilities (%)
 Overall non-lab 56.32 49.60 54.83 49.77 53.20 49.90 54.88 49.76 55.50 49.7 55.66 49.68
 Cardiology 6.09 23.92 5.75 23.28 5.64 23.07 6.40 24.47 6.45 24.57 6.87 25.29
 Pulmonology 4.09 19.79 4.35 20.40 4.18 20.02 4.10 19.83 4.49 20.7 4.91 21.61
  Diabetes 2.08 14.28 2.23 14.78 2.44 15.43 2.03 14.11 2.36 15.18 2.68 16.15
 Overall lab 30.29 45.95 31.55 46.47 32.05 46.67 30.12 45.88 31.98 46.64 33.57 47.22
 Cardiology 1.74 13.07 1.62 12.63 1.66 12.77 1.49 12.13 2.47 15.53 3.08 17.29
 Pulmonology 0.33 5.73 0.33 5.76 0.32 5.67 0.32 5.66 0.34 5.83 0.32 5.65
 Diabetes 0.82 9.01 0.75 8.64 0.74 8.57 0.54 7.32 0.94 9.64 1.15 10.64
Outpatient case numbers (per 100 inhabitants)
 Overall non-lab 297.38 594.18 291.16 580.61 290.65 589.24 280.47 549.11 303.66 591.37 329.49 645.38
 Cardiology 11.98 62.00 11.16 62.06 11.13 66.01 12.76 65.12 13.38 72.94 14.49 73.89
 Pulmonology 8.17 59.19 8.95 68.03 8.67 68.13 7.92 54.26 8.57 58.47 9.06 61.45
 Diabetes 5.11 46.47 5.19 45.74 5.51 45.96 5.07 45.92 5.69 47.98 6.65 52.93
 Overall lab 99.61 329.79 106.96 351.26 107.06 344.69 99.51 346.38 114.18 382.26 124.83 384.04
 Cardiology 2.93 32.17 3.00 38.19 2.96 34.56 2.77 33.17 4.24 41.95 5.26 42.62
 Pulmonology 0.78 32.41 0.74 22.78 0.73 25.88 0.54 12.5 0.62 15.69 0.56 15.10
 Diabetes 1.50 21.87 1.33 19.44 1.31 19.21 1.07 20.04 1.67 22.92 2.17 26.07
Outpatient expenditures (1000 HUF/inhabitant)
 Overall 9.54 25.51 9.76 27.75 10.38 28.19 9.31 25.94 10.23 27.8 11.90 29.87
 N. of obs. 944,550 1,427,989 1,426,575 893,343 1,356,140 1,363,032
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